Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.89 USD | +5.19% |
|
-21.85% | +10.68% |
Jun. 04 | Oppenheimer Initiates Cartesian Therapeutics With Outperform Rating, $50 Price Target | MT |
May. 24 | Mizuho Securities Starts Cartesian Therapeutics With Buy Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.68% | 407M | |
+15.85% | 122B | |
+18.91% | 113B | |
+7.51% | 22.84B | |
-18.63% | 20.72B | |
-13.76% | 16.39B | |
-15.57% | 16.51B | |
-43.53% | 15.83B | |
+1.75% | 13.49B | |
+28.07% | 11.67B |
- Stock Market
- Equities
- RNAC Stock
- News Cartesian Therapeutics, Inc.
- Transcript : Selecta Biosciences, Inc. - Shareholder/Analyst Call